CU News
News from the University of Colorado in Boulder.
Colorado business confidence remains positive going into first quarter, says CU Leeds School index
Jan 2nd
For the first quarter of 2013 the LBCI, conducted by the Leeds School’s Business Research Division, posted an overall confidence reading of 51.3, down slightly from 51.6 in the fourth quarter of 2012. A reading greater than the neutral mark of 50 indicates positive expectations and one less than 50 indicates negative expectations going forward
Business leaders are optimistic about all of the metrics of the quarterly index except for the national economy and industry hiring plans. The other categories measured include the state economy, industry sales, industry profits and capital expenditures.
“For months, drags on the national economy have included the European debt crisis, the slow rate of employment growth and the resolution of the federal debt crisis,” said economist Richard Wobbekind, executive director of the Business Research Division. “While Colorado business leaders have stronger confidence in the local economy than the national economy, they’re proceeding very cautiously.”
Confidence in the state economy, which is at 55.5 points for the first quarter of 2013, outstrips that of the national economy, which posted a reading of 47. The outpacing of confidence in Colorado’s economy compared to the national economy is a 30-quarter trend, based on LBCI results.
Business leaders’ sales expectations for the first quarter rose to 54.4, up from 53.2 last quarter, and are buoyed by 44.1 percent of LBCI respondents who anticipate an increase in the first quarter versus only 25.2 percent who predict a decline. Meanwhile, leaders’ profit expectations fell to 51.6, down from 52.2 for the last quarter of 2012.
Hiring expectations have slipped into negative territory at 49.3, down from 51 in the last quarter of 2012, while capital expenditures remain close to neutral at 50.1.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
CU-Boulder team develops swarm of pingpong ball-sized robots
Dec 14th
Correll and his computer science research team, including research associate Dustin Reishus and professional research assistant Nick Farrow, have developed a basic robotic building block, which he hopes to reproduce in large quantities to develop increasingly complex systems.
Recently the team created a swarm of 20 robots, each the size of a pingpong ball, which they call “droplets.” When the droplets swarm together, Correll said, they form a “liquid that thinks.”
To accelerate the pace of innovation, he has created a lab where students can explore and develop new applications of robotics with basic, inexpensive tools.
Similar to the fictional “nanomorphs” depicted in the “Terminator” films, large swarms of intelligent robotic devices could be used for a range of tasks. Swarms of robots could be unleashed to contain an oil spill or to self-assemble into a piece of hardware after being launched separately into space, Correll said.
Correll plans to use the droplets to demonstrate self-assembly and swarm-intelligent behaviors such as pattern recognition, sensor-based motion and adaptive shape change. These behaviors could then be transferred to large swarms for water- or air-based tasks.
Correll hopes to create a design methodology for aggregating the droplets into more complex behaviors such as assembling parts of a large space telescope or an aircraft.
In the fall, Correll received the National Science Foundation’s Faculty Early Career Development award known as “CAREER.” In addition, he has received support from NSF’s Early Concept Grants for Exploratory Research program, as well as NASA and the U.S. Air Force.
He also is continuing work on robotic garden technology he developed at the Massachusetts Institute of Technology in 2009. Correll has been working with Joseph Tanner in CU-Boulder’s aerospace engineering sciences department to further develop the technology, involving autonomous sensors and robots that can tend gardens, in conjunction with a model of a long-term space habitat being built by students.
Correll says there is virtually no limit to what might be created through distributed intelligence systems.
“Every living organism is made from a swarm of collaborating cells,” he said. “Perhaps some day, our swarms will colonize space where they will assemble habitats and lush gardens for future space explorers.”
For a short video of Correll’s team developing swarm droplets visit http://www.colorado.edu/news/multimedia/researchers-creating-team-tiny-robots. For more information about CU-Boulder’s computer science department visit http://www.colorado.edu/engineering/academics/degree/computer-science.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
CU : Some good news for doggie lovers
Dec 11th
clinical study to treat canine pain
A University of Colorado Boulder professor and her biomedical spinoff company Xalud Therapeutics Inc. of San Francisco are teaming up with a Front Range veterinarian to conduct a clinical study targeting an effective treatment for dogs suffering from chronic pain.
Distinguished Professor Linda Watkins of CU-Boulder’s psychology and neuroscience department said the study involves treating ailing dogs with a gene therapy using Interleukin-10, or IL-10, a protein and anti-inflammatory that both dogs and humans produce naturally. Watkins is working with veterinarian Robert Landry of Mountain Ridge Animal Hospital and Pain Management Center in Lafayette, who will be treating canine patients suffering from chronic and painful conditions, some of which already are being treated with various other medications with limited success.

Animals perceive and experience several levels of pain that are similar to humans, and chronic pain can be debilitating and also shorten the lives of pets, said Landry, one of only a handful of credentialed American Academy of Pain Management practitioners in Colorado. Landry currently is seeking Denver-Boulder area pet owners who have dogs suffering from chronic pain and who might be interested in participating in the study, which is free.
The new study is driven by research spearheaded by Watkins indicating a type of cell known as glial cells found in the nervous system of mammals plays a key role in pain. Under normal conditions, glial cells act as central nervous system “housekeepers,” cleaning up cellular debris and providing support for neurons, said Watkins. But glial cells also can play a pivotal role in pain enhancement by exciting neurons that both transmit pain signals and release a host of chemical compounds that cause problems like chronic neuropathic pain and other medical issues.
The team will use Xalud’s lead product candidate, XT-101, a gene therapy that harnesses the power of the potent anti-inflammatory IL-10 to normalize glial activity and eliminate neuropathic pain for up to 90 days with a single injection.

The gene therapy based on IL-10 has a number of advantages, including suppressing glial activity in the spinal cord, stimulating tissue regeneration and growth, decreasing the production of pro-inflammatory substances and increasing the production of anti-inflammatory substances, Watkins said. Landry and Watkins also have been working with the American Kennel Club on potential funding for additional clinical studies involving the treatment of chronic pain in dogs, said Watkins.
“We have already tested this new therapy in two pet dogs, and both have had remarkable reversals of their pain for long durations after a single injection of the therapeutic,” she said. “Our early peek at the potential of this therapeutic treatment in dogs shows essentially the same positive effects we have seen in laboratory rats used in our studies that have been treated with the therapy.”
Watkins said demonstrating the efficacy and safety of the new gene therapy in a second species of mammal is important in terms of moving it forward to eventually meet FDA regulations for human clinical trials.
In addition to studying what triggers glial cells to become activated and begin releasing pain-enhancing substances and ways to control chronic pain, Watkins and her research team recently discovered that clinically prescribed opioids also activate glial cells and cause them to release pain-enhancing substances. “Our ultimate goal is to find a means by which clinical pain control can be improved so as to relieve human suffering,” she said.
To contact Landry about possible participation in the study by family dogs suffering chronic pain and that might benefit from the experimental treatment, call the Mountain Ridge Animal Hospital at 303-665-4852.
For more information on CU-Boulder’s psychology and neuroscience department visit http://psych-www.colorado.edu/. For more information on Xalud Therapeutics Inc. visit http://www.xaludthera.com/. For more information on Mountain Ridge Animal Hospital visit http://www.mountainridgevet.com/.
[includeme src=”http://c1n.tv/boulder/media/bouldersponsors.html” frameborder=”0″ width=”670″ height=”300″]
–





















